Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance

Amneal Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.05 revenue$557,540,000

Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).
Adjusted EBITDA $115-120M, up ~18% YoY.
Long-term debt $2.692B; net debt reduced to $2.541B from $2.647B at Dec 31.
Management cites strong generics, biosimilars uptake, Rytary/Unithroid growth; IPX203 PDUFA June 30.
Full year 2023 financial guidance affirmed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $550 million to $560 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $550 million to $560 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

2023. Unaudited Preliminary Financial Results for the First Quarter Ended March 31, 2023 Based on preliminary financial information, Amneal expects to report: • Net revenue of $550 million to $560 million, an increase of approximately 12% compared to the first quarter of 2022 • Loss before income taxes of $10 million to $0, an improvement of approximately 50%

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.